<DOC>
	<DOCNO>NCT01272804</DOCNO>
	<brief_summary>The purpose study characterize safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) PF-04937319 follow multiple ( 14 day ) escalate oral dos patient type 2 diabetes .</brief_summary>
	<brief_title>Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients type 2 diabetes mellitus take metformin . Treatment stable , defined change treatment , include dose , past 2 month . Regimens may include daily twice daily dose . Male and/or female patient ( female woman non childbearing potential ) Body Mass Index ( BMI ) 18.5 45.0 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . HbA1c 7.0 % 10.0 % . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Patients chronic condition T2DM ( example , hypercholesterolemia hypertension ) control either diet stable ( last 2 month ) dose medication may include well ( example , subject hypercholesterolemia appropriate treatment eligible ) . Evidence history diabetic complication significant end organ damage , eg , proliferative retinopathy and/or macular edema , creatinine clearance le 60 mL/min Any condition possibly affect drug absorption ( eg , gastrectomy ) History stroke transient ischemic attack myocardial infarction within past 6 month History coronary artery bypass graft stent implantation . Clinically significant peripheral vascular disease ( eg , manifested claudication ) . Any history clinical evidence congestive heart failure , NYHA Classes II IV . One self report significant/severe/requiring treatment episode hypoglycemia within last 3 month , two self report significant/severe/requiring treatment episode hypoglycaemia within last 6 month . Current history angina/unstable angina . Milk soy allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacokinetics PK Pharmacodynamics PD T2DM Phase 1 Type 2 diabetes mellitus safety tolerability</keyword>
</DOC>